Federal Circuit Reverses $1.2 Billion Judgment Against Client Gilead Sciences
| August.26.2021
The U.S. Court of Appeals for the Federal Circuit today overturned a $1.2+ billion patent infringement judgment against Gilead’s Kite Pharma unit.
Client Results
Orrick Advises Cerba HealthCare in Acquisition of Lifebrain
| July.26.2021
Attilio Mazzilli led a team that assisted Cerba HealthCare, a leader in outpatient diagnostics, in the acquisition of the entire stake of Lifebrain.
Orrick Advises HCW Biologics on $56 Million IPO
| July.20.2021
Orrick is advising HCW Biologics on its $56 million initial public offering of 7 million shares of common stock.
Orrick Advises Rafael Pharmaceuticals on Merger with Rafael Holdings
| June.21.2021
Orrick is advising Rafael Pharmaceuticals, a clinical-stage oncology company, on its proposed merger with Rafael Holdings.
Orrick Advises SOC Telemed on $194 Million Acquisition of Access Physicians
| March.31.2021
This combination furthers SOC Telemed's position as the largest pure-play provider of acute care telemedicine in the nation.
Orrick Team Obtains Landmark Referral to EU Top Court for Roche in Italian Pharma Antitrust Dispute
| March.30.2021
Our Italy team is advising Roche in a high-profile case at the intersection of competition law and pharmaceutical sector regulation.
Orrick Advises GuideTx on Acquisition by Beam Therapeutics
| February.23.2021
We advised Guide Therapeutics, a developer of nonviral drug delivery vehicles for genetic medicines, on its acquisition by biotech company Beam ...
International Arbitration Team Secures Major Win for Pioneering Swiss Non‐Profit Research Foundation EspeRare
| January.29.2021
The outcome validated EspeRare’s rescission, on grounds of fraud in the inducement, of an R & D collaboration agreement.
Orrick Advises Catalyst Biosciences on Underwritten Public Offering
| January.27.2021
Congratulations to Catalyst Biosciences, Inc. (Nasdaq: CBIO), a clinical-stage biopharmaceutical company, on its underwritten public offering.
Orrick Advises K Health on $132 Million Series E Round
| January.20.2021
Congratulations to our healthcare technology client K Health on its $132 million Series E financing round.
Insights
Cybersecurity and Privacy Threats and Risks for Life Sciences and Healthcare Companies
by Thora Johnson, Keily Blair, Adele Harrison and Hannah Levin | July.22.2021
Attacks on the life sciences and healthcare sectors increased significantly in the last year.
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q3 2021
| July.21.2021
A Conversation on Spinouts – Unlocking Market Value and Creating Business Opportunities
Life Sciences Snapshot – A Quarterly Report on Financing Trends – Q2 2021
| April.20.2021
Record-breaking Markets and a Candid Conversation on University Spinouts
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q1 2021
| February.01.2021
We review full-year 2020 data in depth to identify and summarize the key trends that shaped venture investment across the sector.
Using M&A Insurance on Tech Deals (Issue 3): Fintech, edtech and healthtech/medtech
by Peter M. Lamb, David M. Ruff, Hari Raman, Daniel Lopez and Zac Padgett | January.21.2021
We dig deeper into key underwriting topics for fintech, edtech and healthtech/medtech deals.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q3 2020
| October.22.2020
Venture Surges and the Rise of SPACs
In this edition, the traditional update on broader venture market financing data is included.
In this edition, the traditional update on broader venture market financing data is included.
Investments in Germany under COVID 19 – Turning a Crisis into Opportunities
by Dr. Oliver Duys LL.M. (UNSW Sydney), Abhijit Narayan and Hayat Makhloufi | August.17.2020
This article provides an overview about the recent investment trends in Germany in view of the COVID-19 pandemic.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q2 2020
| August.10.2020
Companies & Investors Navigate the Pandemic Era
In this new series, we explore trends in venture investing across the life sciences sector.
In this new series, we explore trends in venture investing across the life sciences sector.
China Proposes to Tighten Biosecurity Law and its Potential Impact on Foreign Pharmaceutical and Biotech Companies Operating in China
by , Yufeng (Ethan) Ma and Martha Wang | July.10.2020
On April 26, 2020, the Standing Committee of the National People's Congress, China’s top legislature, passed the second draft of the country’s ...
Board Oversight of Clinical Trials During the Pendency of the COVID-19 Pandemic
by Albert Vanderlaan and Stephen Thau | June.19.2020
COVID-19 has had far-reaching social, economic and regulatory impacts. Nearly all companies (private and public, large and small) have had reason to ...
Direct Listings May Pose Challenges for Cash Intensive Life Sciences Companies
by Albert Vanderlaan | May.14.2020
Are direct listings a viable potential alternative for all companies seeking to go public? The answer may likely be no.
Managing and Maintaining Clinical Trial Disclosure for Publicly Traded Life Sciences Companies
by Albert Vanderlaan | May.21.2020
The following discussion is intended to help guide companies in making clinical trial-related disclosures.
Life Sciences Snapshot ‐ A Quarterly Report on Financing Trends ‐ Q1 2020
| May.11.2020
The Market Meets COVID-19
In this new series, we explore trends in venture investing across the life sciences sector.
In this new series, we explore trends in venture investing across the life sciences sector.
Dusting the Regulatory Framework – French Competition Authority Seeks to Liberalize Distribution of Drugs and Private Medical Biology
by Marie-Laure Combet and Elise Durand | April.26.2019
On April 4, 2019, just three months after the publication of the European Commission (EC) report on “Competition enforcement in the pharmaceutical ...
Profiles in Innovation: Twist Bioscience’s Co-Founder Navigates Company from Start-up to Public Company
| February.21.2019
Emily Leproust discusses her inspiration and journey building a public company in the fast growing synthetic DNA market with commentary from Orrick ...
News
Orrick Expands Cyber & Privacy Team with a Health Tech Focus
| July.07.2021
Orrick announced today that Thora Johnson has joined our Cyber, Privacy & Data Innovation practice as a partner in Washington, DC.
Veteran Advisor Mike O’Donnell Joins Orrick’s Life Sciences Team
| July.01.2021
Welcome Mike O’Donnell, a leading advisor to the Life Sciences sector, who has joined the firm as a partner in Silicon Valley. He is the 9th addition ...
Orrick Adds Patent Prosecution Leader to Fast Growing Life Sciences Team
| March.15.2021
Gargi Talukder, a recognized leader in protecting the innovations of life sciences companies, has joined the firm as a partner in San Francisco.
Orrick Adds Life Sciences Authority David Schulman
| January.25.2021
Orrick announced today that premier life sciences advisor David Schulman has joined the firm as a partner in Washington, D.C.